Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Licenses Proteomics Technology from Large Scale Biology and Millennium

NEW YORK, Oct. 10 - Agilent Technologies said today it will license proteomics sample preparation technology from Large Scale Biology.

 

The agreement will allow Agilent to exclusively develop new technologies for the separation of low-abundance proteins from serum samples, said Agilent.

 

Financial details of the agreement were not disclosed.

 

In a separate deal, Agilent has licensed the right to exclusively develop and sell software based on Millennium Pharmaceuticals' SpectrumMill mass spectral analysis software. Agilent said the software will help its customers get more information from the company's mass spectrometry-based proteomics products.

 

The agreement gives Millennium early access to Agilent products and chemistries for proteomics research, according to Agilent.

 

The companies did not disclose financial details of the agreement.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.